Pyxis Oncology (NASDAQ:PYXS) had its "overweight" rating reaffirmed by analysts at Stephens.
Pyxis Oncology (NASDAQ:PYXS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Pyxis Oncology (NASDAQ:PYXS) was given a new $7.00 price target on by analysts at Guggenheim.
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology (NASDAQ:PYXS) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $9.00 price target on the stock.